Checkpoint Inhibitors: Past, Present and Future

Moderator(s)

• 

  Anne Bass, MD

  Hospital for Special Surgery, Weill Cornell Medicine

Speaker(s)

• JW

  Jedd Wolchok, MD, PhD

  Memorial Sloan Kettering Cancer Center
• 

  Laura Cappelli, MD

  Johns Hopkins School of Medicine

With the increased usage of immune checkpoint inhibition for the management of malignancies, rheumatologists and oncologists increasingly encounter patients with rheumatologic immune-related adverse events (IRAE). This lecture covers the history and development of immune checkpoint inhibitors (ICI), current uses and complications of these agents, and new checkpoint inhibitors in development. Faculty will present the perspectives of both an oncologist and rheumatologist on the challenges they have encountered when patients develop rheumatologic IRAE, while being treated with ICI--therapies that are often highly effective treatments of their malignancies. This session will review strategies for managing these adverse events in this patient population.

Learning Objectives:

• Explain the mechanism of action of checkpoint inhibitors
• Recognize immune-related adverse events associated with the use of immune checkpoint inhibitors
• Review strategies for managing rheumatologic immune-related adverse events associated with immune checkpoint inhibitor therapy
• Identify new immune checkpoint inhibitors in late stages of development

Presentations:

• 3:00 PM – 3:20 PM ET

  Update on the Use of Checkpoint Inhibitors: An Oncologist's Perspective
  Jedd Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
• 3:20 PM – 3:40 PM ET

  Management of Rheumatologic Immune-Related Adverse Events Associated with Checkpoint Inhibition
  Laura Cappelli, MD – Johns Hopkins School of Medicine
• 3:40 PM – 4:00 PM ET

  Q&A